Tag Archives: Pfizer

A pedestrian walks past Pfizer Inc. headquarters in New York, U.S., on Monday, Nov. 23, 2015. Photographer: Michael Nagle/Bloomberg

Pfizer-Allergan Merger Redo Seen Unlikely as Tax Rule Rejected

Pfizer-Allergan Merger Redo Seen Unlikely as Tax Rule Rejected

By Lynnley Browning, Bloomberg News A federal judge last week overturned a tax regulation that stopped the planned $160 billion merger between Pfizer Inc. and Ireland-based Allergan Plc last year– but the ruling doesn’t necessarily mean the deal would be revived, experts said. The proposed merger drew nationwide outcry over the prospect that it would

A pedestrian walks past Pfizer Inc. headquarters in New York, U.S., on Monday, Nov. 23, 2015. Photographer: Michael Nagle/Bloomberg

Pfizer Faces Revived Shareholder Suit Over Celebrex, Bextra

By Christie Smythe, Bloomberg News Pfizer Inc. must face a shareholders’ lawsuit accusing the company of misrepresenting risks associated with the arthritis drugs Celebrex and Bextra, according to a federal appeals court. The class action alleged Pfizer officials hid information about studies that suggested use of the drugs may result in increased risks of heart attacks

A pedestrian walks past Pfizer Inc. headquarters in New York, U.S., on Monday, Nov. 23, 2015. Photographer: Michael Nagle/Bloomberg

Five Facts: Pfizer’s and Allergan’s Top Lawyers

On Wednesday, the $160 billion merger between pharmaceutical giants Pfizer and Allergan was called off in response to new U.S. Treasury Department regulations aimed at preventing so-called inversion deals — which allow U.S. companies to move their bases overseas in search of more favorable tax environments. The combination would have been a record size for pharmaceutical companies, and was also

Photo by stokpic (Pixabay)

Women Rise Swiftly in the Privacy Field

Editor’s Note: This article is a companion piece to a survey by the International Association of Privacy Professionals, which previously appeared on Big Law Business and showed gender parity in pay for privacy officers. The author of this post is the editor of the IAPP’s monthly member publication, The Privacy Advisor.  By Angelique Carson, Editor

system-71228_1280

Week One: Who We Heard From, And What They Said

Photo by geralt (Pixabay) One week out from the launch of Big Law Business, we’d like to highlight some of our most popular content brought to you over the past seven days by the people who make up our community.   Spotlight Profiles: • H. Rodgin Cohen, Senior Chairman of Sullivan & Cromwell, told us how the

Ballard Spahr offered perhaps the first AFA in Big Law in the 1990s

Pfizer, Robins Kaplan, Take On Alternative Fee Arrangements

Photo by 401(K)2012 (Flickr/ Creative Commons) The alternative fee arrangement continues to be a favorite tool of pinched corporate clients to drive down legal fees. According to Altman Weil’s 2014 Chief Legal Officer Survey, almost 60 per cent of corporate legal departments used AFAs last year to control costs. On Tuesday, at a conversation hosted

Top